Eyepoint Pharmaceuticals Stock Buy Hold or Sell Recommendation
| EYPT Stock | USD 17.65 0.15 0.86% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Eyepoint Pharmaceuticals is 'Hold'. Macroaxis provides Eyepoint Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding EYPT positions. The advice algorithm takes into account all of Eyepoint Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Eyepoint Pharmaceuticals' buy or sell advice are summarized below:
Real Value 20.47 | Target Price 31.75 | Hype Value 18.09 | Market Value 17.65 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Eyepoint Pharmaceuticals given historical horizon and risk tolerance towards Eyepoint Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Eyepoint Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Eyepoint |
Execute Eyepoint Pharmaceuticals Buy or Sell Advice
The Eyepoint recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Eyepoint Pharmaceuticals. Macroaxis does not own or have any residual interests in Eyepoint Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Eyepoint Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Eyepoint Pharmaceuticals Trading Alerts and Improvement Suggestions
| Eyepoint Pharmaceuticals generated a negative expected return over the last 90 days | |
| Eyepoint Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 46.02 M. Net Loss for the year was (70.8 M) with profit before overhead, payroll, taxes, and interest of 26.95 M. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: EyePoint Pharmaceuticals Sees Strong Trading Volume - MarketBeat |
Eyepoint Pharmaceuticals Returns Distribution Density
The distribution of Eyepoint Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Eyepoint Pharmaceuticals' future price movements. The chart of the probability distribution of Eyepoint Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Eyepoint Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Eyepoint Pharmaceuticals returns is essential to provide solid investment advice for Eyepoint Pharmaceuticals.
| Mean Return | -0.25 | Value At Risk | -5.21 | Potential Upside | 5.87 | Standard Deviation | 3.96 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Eyepoint Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Eyepoint Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eyepoint Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eyepoint Pharmaceuticals backward and forwards among themselves. Eyepoint Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Eyepoint Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2023-12-31 | 1.1 M | Millennium Management Llc | 2023-12-31 | 1.1 M | Jennison Associates Llc | 2023-12-31 | 1.1 M | Citadel Advisors Llc | 2023-09-30 | 1.1 M | Deutsche Bank Ag | 2023-12-31 | 770.5 K | Geode Capital Management, Llc | 2023-12-31 | 682.4 K | Federated Hermes Inc | 2023-12-31 | 674.8 K | Perceptive Advisors Llc | 2023-12-31 | 589.6 K | Ubs Group Ag | 2023-12-31 | 574.2 K | Cormorant Asset Management, Llc | 2023-12-31 | 6 M | Franklin Resources Inc | 2023-12-31 | 4.6 M |
Eyepoint Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (23.0M) | 22.7M | 133.7M | (83.0M) | 185.6M | 194.9M | |
| Free Cash Flow | (56.9M) | (14.8M) | (50.3M) | (67.2M) | (1.6M) | (1.7M) | |
| Depreciation | 2.6M | 2.6M | 2.8M | 2.4M | 464K | 440.8K | |
| Other Non Cash Items | 1.6M | 1.7M | 628K | 23.6M | 1.2M | 1.1M | |
| Capital Expenditures | 213K | 362K | 156K | 2.2M | 3.5M | 3.7M | |
| Net Income | (56.8M) | (45.4M) | (58.4M) | (102.3M) | (70.8M) | (67.3M) | |
| End Period Cash Flow | 22.4M | 45.1M | 178.7M | 95.8M | 281.3M | 295.3M | |
| Change To Inventory | (1.9M) | (3.2M) | 1.3M | (760K) | (1.6M) | (1.5M) | |
| Investments | (33.0M) | (213K) | (362K) | (15.1M) | (3.3M) | (3.5M) | |
| Change To Netincome | 9.4M | 7.4M | 6.7M | 38.4M | 44.1M | 46.3M | |
| Net Borrowings | 25.9M | (14.6M) | (146K) | (653K) | (587.7K) | (558.3K) |
Eyepoint Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Eyepoint Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Eyepoint Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Eyepoint stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.39 | |
β | Beta against NYSE Composite | 1.79 | |
σ | Overall volatility | 3.84 | |
Ir | Information ratio | -0.08 |
Eyepoint Pharmaceuticals Volatility Alert
Eyepoint Pharmaceuticals exhibits very low volatility with skewness of -0.76 and kurtosis of 3.17. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Eyepoint Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Eyepoint Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Eyepoint Pharmaceuticals Fundamentals Vs Peers
Comparing Eyepoint Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Eyepoint Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Eyepoint Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Eyepoint Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Eyepoint Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Eyepoint Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Eyepoint Pharmaceuticals to competition |
| Fundamentals | Eyepoint Pharmaceuticals | Peer Average |
| Return On Equity | -0.39 | -0.31 |
| Return On Asset | -0.17 | -0.14 |
| Profit Margin | (1.54) % | (1.27) % |
| Operating Margin | (1.08) % | (5.51) % |
| Current Valuation | 553.93 M | 16.62 B |
| Shares Outstanding | 49.83 M | 571.82 M |
| Shares Owned By Insiders | 1.02 % | 10.09 % |
| Shares Owned By Institutions | 98.98 % | 39.21 % |
| Number Of Shares Shorted | 6.85 M | 4.71 M |
| Price To Earning | (2.82) X | 28.72 X |
| Price To Book | 4.20 X | 9.51 X |
| Price To Sales | 24.31 X | 11.42 X |
| Revenue | 46.02 M | 9.43 B |
| Gross Profit | 26.95 M | 27.38 B |
| EBITDA | (73.2 M) | 3.9 B |
| Net Income | (70.8 M) | 570.98 M |
| Cash And Equivalents | 171.17 M | 2.7 B |
| Cash Per Share | 5.02 X | 5.01 X |
| Total Debt | 5.47 M | 5.32 B |
| Debt To Equity | 0.30 % | 48.70 % |
| Current Ratio | 6.16 X | 2.16 X |
| Book Value Per Share | 5.43 X | 1.93 K |
| Cash Flow From Operations | 1.88 M | 971.22 M |
| Short Ratio | 6.88 X | 4.00 X |
| Earnings Per Share | (1.82) X | 3.12 X |
| Target Price | 43.67 | |
| Number Of Employees | 121 | 18.84 K |
| Beta | 1.68 | -0.15 |
| Market Capitalization | 879.51 M | 19.03 B |
| Total Asset | 355.18 M | 29.47 B |
| Retained Earnings | (742.15 M) | 9.33 B |
| Working Capital | 281.54 M | 1.48 B |
| Current Asset | 15.08 M | 9.34 B |
Note: Disposition of 7962 shares by Nancy Lurker of Eyepoint Pharmaceuticals at 28.8 subject to Rule 16b-3 [view details]
Eyepoint Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Eyepoint . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Eyepoint Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Eyepoint Pharmaceuticals? Buying financial instruments such as Eyepoint Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 38.4M | 45.8M | 5.5M | 5.2M | Total Assets | 263.4M | 180.4M | 355.2M | 372.9M |
Use Investing Ideas to Build Portfolios
In addition to having Eyepoint Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Mid Cap ETFs Thematic Idea Now
Mid Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Eyepoint Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Eyepoint Stock analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Eyepoint Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyepoint Pharmaceuticals. If investors know Eyepoint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyepoint Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Revenue Per Share 1.183 | Quarterly Revenue Growth 0.332 | Return On Assets (0.17) | Return On Equity (0.39) |
The market value of Eyepoint Pharmaceuticals is measured differently than its book value, which is the value of Eyepoint that is recorded on the company's balance sheet. Investors also form their own opinion of Eyepoint Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eyepoint Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyepoint Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eyepoint Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyepoint Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyepoint Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyepoint Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.